Relmada Free Cash Flow vs End Period Cash Flow Analysis
| RLMD Stock | USD 0.47 0.01 2.08% |
Relmada Therapeutics financial indicator trend analysis is much more than just breaking down Relmada Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Relmada Therapeutics is a good investment. Please check the relationship between Relmada Therapeutics Free Cash Flow and its End Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.
Free Cash Flow vs End Period Cash Flow
Free Cash Flow vs End Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Relmada Therapeutics Free Cash Flow account and End Period Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Relmada Therapeutics' Free Cash Flow and End Period Cash Flow is -0.46. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Relmada Therapeutics, assuming nothing else is changed. The correlation between historical values of Relmada Therapeutics' Free Cash Flow and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Relmada Therapeutics are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Free Cash Flow i.e., Relmada Therapeutics' Free Cash Flow and End Period Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.46 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.End Period Cash Flow
Most indicators from Relmada Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Relmada Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.At present, Relmada Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 25.77, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.98.
| 2021 | 2023 | 2024 (projected) | Total Operating Expenses | 125.7M | 103.7M | 108.9M | Cost Of Revenue | 1.3K | 1.1K | 1.1K |
Relmada Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Relmada Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Relmada Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.2M | 118.2M | 223.3M | 152.9M | 97.6M | 60.8M | |
| Total Current Liabilities | 2.6M | 12.6M | 15.1M | 12.5M | 12.2M | 9.2M | |
| Total Stockholder Equity | 7.6M | 105.6M | 208.3M | 140.4M | 85.4M | 43.3M | |
| Net Debt | (8.9M) | (2.5M) | (44.4M) | (5.4M) | (4.1M) | (4.3M) | |
| Retained Earnings | (111.7M) | (179.3M) | (305.1M) | (462.1M) | (560.9M) | (532.9M) | |
| Accounts Payable | 924.4K | 8.3M | 11.2M | 5.3M | 3.5M | 3.0M | |
| Cash | 9.2M | 2.5M | 44.4M | 5.4M | 4.1M | 3.9M | |
| Cash And Short Term Investments | 9.2M | 117.1M | 211.9M | 148.3M | 96.3M | 58.5M | |
| Common Stock Total Equity | 39.0K | 14.5K | 16.3K | 30.1K | 27.1K | 25.7K | |
| Common Stock Shares Outstanding | 6.3M | 15.6M | 17.6M | 29.6M | 30.1M | 31.6M | |
| Liabilities And Stockholders Equity | 10.2M | 118.2M | 223.3M | 152.9M | 97.6M | 61.0M | |
| Non Current Liabilities Total | 2.7M | 1.3M | 8.3M | 11.2M | 5.3M | 0.0 | |
| Inventory | 459K | 903.2K | 11.3M | 4.0M | 4.6M | 4.9M | |
| Other Current Assets | (55.0) | 903.2K | 11.3M | 4.0M | 1.2M | 1.6M | |
| Total Liab | 2.6M | 12.6M | 15.1M | 12.5M | 12.2M | 9.4M | |
| Total Current Assets | 10.0M | 118.1M | 223.3M | 152.9M | 97.5M | 60.6M | |
| Common Stock | 9.7K | 16.3K | 27.7K | 30.1K | 27.1K | 16.5K | |
| Other Current Liab | (45.0) | 4.3M | 3.9M | 7.2M | 8.7M | 7.4M | |
| Net Tangible Assets | 115.7M | 105.6M | 208.3M | 140.4M | 161.5M | 169.6M | |
| Non Current Assets Total | 235.4K | 112.6K | 28.3K | 34.9K | 43.1K | 41.0K | |
| Capital Surpluse | 88.8M | 119.2M | 235.5M | 602.5M | 692.9M | 727.5M | |
| Other Stockholder Equity | 119.3M | 284.9M | 513.3M | 602.5M | 646.2M | 678.5M | |
| Property Plant And Equipment Gross | 7.2K | 5K | 1.3K | 16.7K | 15.0K | 14.3K | |
| Property Plant Equipment | 12.1K | 7.2K | 5.0K | 1.3K | 1.1K | 1.1K | |
| Other Assets | 190.8K | 111.4K | 28.3K | 34.9K | 31.4K | 29.8K | |
| Net Receivables | 308.9K | 79.5K | 86.4K | 512.4K | 589.3K | 618.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.